Loading organizations...
Cajal Neuroscience is a technology company.
Cajal Neuroscience develops a platform for target and drug discovery in neurodegenerative diseases. It integrates human genetics, functional genomics, and advanced microscopy to map disease mechanisms. This enables identification and validation of therapeutic targets for conditions like Parkinson's and Alzheimer's with high spatial and temporal resolution.
Founded in 2020, Cajal Neuroscience emerged from the insight of co-founders Ignacio Muñoz-Sanjuán, Ian Peikon, Andrew Dervan, and Rob Hershberg, alongside scientific co-founders Huda Zoghbi, Anthony Zador, and Charles Zuker. They aimed to revolutionize drug discovery, redefining understanding via integrated science, inspired by Santiago Ramón y Cajal.
Cajal Neuroscience targets patients with neurodegenerative conditions, addressing the urgent demand for effective new therapies. Its vision is to transform the field by discovering novel treatments and establishing a foundational understanding of disease biology. Unraveling mechanisms, Cajal aims to profoundly impact patient care and improve outcomes.
Cajal Neuroscience has raised $96.0M across 1 funding round.
Cajal Neuroscience has raised $96.0M in total across 1 funding round.
Cajal Neuroscience has raised $96.0M in total across 1 funding round.
Cajal Neuroscience's investors include Lux Capital, The Column Group, Dimension Capital, LGF, Alexandria Venture Investments, Bristol Myers Squibb, Dolby Family Ventures, Evotec, Two Sigma Ventures.
Cajal Neuroscience is a Seattle-based biotechnology company that builds an integrated discovery platform to identify and validate genetically‑supported targets and advance therapeutics for neurodegenerative diseases such as Parkinson’s and Alzheimer’s, launched in 2020 with a sizable Series A raise to industrialize high-throughput functional genomics, multi‑omics and advanced imaging for neurodegeneration drug discovery.[3][1]
High‑Level Overview
For a portfolio-company style summary (what Cajal builds and whom it serves)
Origin Story
Core Differentiators
Role in the Broader Tech / Biotech Landscape
Quick Take & Future Outlook
Quick take: Cajal positions itself as a platform‑first biotechnology company aiming to crack the hardest problem in neuroscience—identifying actionable, human‑validated mechanisms for neurodegeneration—backed by substantial Series A capital and industry partnerships that seek to convert its discoveries into therapeutic programs.[3][1]
If you’d like, I can:
Cajal Neuroscience has raised $96.0M across 1 funding round. Most recently, it raised $96.0M Series A in November 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2022 | $96.0M Series A | Lux Capital, The Column Group | Dimension Capital, LGF, Alexandria Venture Investments, Bristol Myers Squibb, Dolby Family Ventures, Evotec, Two Sigma Ventures |